Our objective was to examine the effects of N-methylacetazolamide (NMA), a non-carbonic anhydrase inhibitor, on ischemia-reperfusion injury. Isolated rat hearts were assigned to the following groups: 1) Non-ischemic control (NIC):110 min of perfusion and 2) Ischemic control (IC): 30 min of global ischemia and 60 min of reperfusion (R). Both groups were repeated in presence of NMA (5 uM), administered during the first 10 min of R. Infarct size (IS) was measured by TTC staining. Developed pressure (LVDP) and end-diastolic pressure (LVEDP) of the left ventricle were used to assess systolic and diastolic function, respectively. The content of P-Akt, P-PKCe, PDrp1 and calcineurin AS were measured. In cardiomyocytes the L-type Ca2+ current (ICaL) was recorded with the whole-cell configuration of patch-clamp technique. The addition of NMA to non-ischemic hearts decreased 15% the contractility. In ischemic hearts (IC group), NMA decreased IS (22 & PLUSMN; 2% vs 32 & PLUSMN; 2%, p < 0.05) and improved the post-ischemic recovery of myocardial function. At the end of R, LVDP was 54 & PLUSMN; 7% vs 18 & PLUSMN; 3% and LVEDP was 23 & PLUSMN; 8 vs. 55 & PLUSMN; 7 mmHg & BULL;p < 0.05. & BULL; The level of P-Akt, P-PKCe and P-Drp1 increased and the expression of calcineurin AS decreased in NMA treated hearts. Peak ICaL density recorded at 0 mV was smaller in myocytes treated with NMA than in non-treated cells (-1.91 & PLUSMN; 0.15 pA/pF vs-2.32 & PLUSMN; 0.17 pA/pF, p < 0.05). These data suggest that NMA protects the myocardium against ischemia-reperfusion injury through an attenuation of mitochondrial fission by calcineurin/Akt/PKCe-dependent pathways associated to the decrease of ICaL current.
Cardioprotective effects of N-methylacetazolamide mediated by inhibition of L-type Ca2+ channel current
Pardo, Alejandro Ciocci
;
2022
Abstract
Our objective was to examine the effects of N-methylacetazolamide (NMA), a non-carbonic anhydrase inhibitor, on ischemia-reperfusion injury. Isolated rat hearts were assigned to the following groups: 1) Non-ischemic control (NIC):110 min of perfusion and 2) Ischemic control (IC): 30 min of global ischemia and 60 min of reperfusion (R). Both groups were repeated in presence of NMA (5 uM), administered during the first 10 min of R. Infarct size (IS) was measured by TTC staining. Developed pressure (LVDP) and end-diastolic pressure (LVEDP) of the left ventricle were used to assess systolic and diastolic function, respectively. The content of P-Akt, P-PKCe, PDrp1 and calcineurin AS were measured. In cardiomyocytes the L-type Ca2+ current (ICaL) was recorded with the whole-cell configuration of patch-clamp technique. The addition of NMA to non-ischemic hearts decreased 15% the contractility. In ischemic hearts (IC group), NMA decreased IS (22 & PLUSMN; 2% vs 32 & PLUSMN; 2%, p < 0.05) and improved the post-ischemic recovery of myocardial function. At the end of R, LVDP was 54 & PLUSMN; 7% vs 18 & PLUSMN; 3% and LVEDP was 23 & PLUSMN; 8 vs. 55 & PLUSMN; 7 mmHg & BULL;p < 0.05. & BULL; The level of P-Akt, P-PKCe and P-Drp1 increased and the expression of calcineurin AS decreased in NMA treated hearts. Peak ICaL density recorded at 0 mV was smaller in myocytes treated with NMA than in non-treated cells (-1.91 & PLUSMN; 0.15 pA/pF vs-2.32 & PLUSMN; 0.17 pA/pF, p < 0.05). These data suggest that NMA protects the myocardium against ischemia-reperfusion injury through an attenuation of mitochondrial fission by calcineurin/Akt/PKCe-dependent pathways associated to the decrease of ICaL current.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
